NCT05611684View on ClinicalTrials.gov

The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients

PHASE4RecruitingINTERVENTIONAL

Enrollment

480

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions

Type2 Diabetes Mellitus

Interventions

DRUG

Polyethylene Glycol Losenatide

Treatment 0.2mg QW for 12 weeks

Trial Locations (1)

210006

RECRUITING

Jianhua Ma, Nanjing

All Listed Sponsors

lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT05611684 - The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter